Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-arm, Phase II Interventional Study to Evaluate the Efficacy and Safety of Lomustine Combined With Anlotinib in Patients With Extensive-stage Small Cell Lung Cancer Resistant to Second-line and Further Lines of Treatment

NCT07632209 is registered in ClinicalTrials.gov with Yayi He as lead sponsor.

NCT NCT07632209
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07632209 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-arm, Phase II Interventional Study to Evaluate the Efficacy and Safety of Lomustine Combined With Anlotinib in Patients With Extensive-stage Small Cell Lung Cancer Resistant to Second-line and Further Lines of Treatment
Lead sponsor
Yayi He
Phase
Phase 2
Overall status
Not yet recruiting
Start date
June 30, 2026
Completion date
December 31, 2028
Enrollment
46 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

sclc, extensive stage